MedTrace Logo

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

NCT06381648 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2026-03-13

No results posted yet for this study

Summary

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC.

This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

Conditions

  • Cholangiocarcinoma
  • Cholangiocarcinoma, Intrahepatic
  • Cholangiocarcinoma Resectable
  • Cholangiocarcinoma; Liver

Interventions

DIAGNOSTIC_TEST

LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)

A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ajay Goel, PhD · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-15
Primary Completion
2025-06-01
Completion
2025-07-01

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06381648 on ClinicalTrials.gov